New York, New York 10032

  • Huntington's Disease


The purpose of the study is to collect and assess long term data on the safety, tolerability, and efficacy of pridopidine in patients with Huntington's disease (HD).


Inclusion Criteria: - Pride HD completion within the last 6 months, including 2 week follow up period or patients who transitioned from the Open HART study or patients who complete future safety and efficacy clinical trials of pridopidine. In addition, patients who have already completed their defined study period under Open PRIDE HD global or local amendments and have discontinued treatment with pridopidine will be allowed to re enter the Open PRIDE HD study. - Women of child bearing potential or male participants: Adequate contraception and birth control - Good general health - other criteria apply, please contact the investigator for more information Exclusion Criteria: - Similar baseline criteria for ECG, vital signs, cardiovascular system, and renal function to PRIDE HD; - Similar concomitant medication restrictions to PRIDE HD. - other criteria apply, please contact the investigator for more information



Primary Contact:

Study Director
Teva Medical Expert, MD
Teva Pharmaceuticals USA

Backup Contact:


Location Contact:

New York, New York 10032
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.